Söderström M, Ekfors T, Böhling T, Aho A, Aro H T, Vuorio E
Skeletal Research Program, Department of Medical Biochemistry and Molecular Biology, University of Turku, Turku, Finland.
Matrix Biol. 2001 Jan;19(8):717-25. doi: 10.1016/s0945-053x(00)00124-4.
The aim of the present study was to define the role of cathepsins B, H, K, L and S in the pathogenesis of human chondrosarcomas. For this purpose 40 tumour samples obtained from 12 patients with the diagnosis of conventional chondrosarcoma were systematically investigated for the expression of cathepsin mRNAs by Northern hybridisation, and for immunohistochemical localisation of the proteins. Northern analysis demonstrated the highest levels of cathepsins B and L in a recurring grade 1 chondrosarcoma, and in a grade 3 chondrosarcoma and in fibrous histiocytomas. Increased expression of cathepsin K mRNA was seen in seven chondrosarcomas, as well as in control tumours; fibrous histiocytomas, osteosarcomas, enchondromas and a giant cell tumour of bone. Cathepsin L was immunolocalised within the large chondrocytes, while cathepsin K was predominantly localised in large multinucleated osteoclastic cells and in some hypertrophic chondrocytes. These results suggest that chondrosarcoma can be included in the growing list of tumours, where cathepsins may well be involved in tumour progression. The simultaneous upregulation of cathepsins B and L, together with matrix metalloproteinase-13, and the association of cathepsin K with negative prognostic parameters suggests that an aggressive biological behaviour of chondrosarcoma may be related to the synthesis of cysteine proteinases and activation of other proteolytic enzymes. If this turns out to be the case, cathepsin inhibitors could provide the much needed adjuvant therapy for chondrosarcomas.
本研究的目的是确定组织蛋白酶B、H、K、L和S在人类软骨肉瘤发病机制中的作用。为此,对从12例诊断为传统型软骨肉瘤的患者身上获取的40个肿瘤样本,通过Northern杂交系统研究组织蛋白酶mRNA的表达情况,并对蛋白质进行免疫组织化学定位。Northern分析表明,在复发性1级软骨肉瘤、3级软骨肉瘤以及纤维组织细胞瘤中,组织蛋白酶B和L的水平最高。在7例软骨肉瘤以及对照肿瘤(纤维组织细胞瘤、骨肉瘤、内生软骨瘤和骨巨细胞瘤)中,观察到组织蛋白酶K mRNA表达增加。组织蛋白酶L免疫定位在大软骨细胞内,而组织蛋白酶K主要定位于大型多核破骨细胞和一些肥大软骨细胞中。这些结果表明,软骨肉瘤可被纳入越来越多的可能与组织蛋白酶有关的肿瘤名单中。组织蛋白酶B和L与基质金属蛋白酶-13的同时上调,以及组织蛋白酶K与不良预后参数的关联,提示软骨肉瘤的侵袭性生物学行为可能与半胱氨酸蛋白酶的合成以及其他蛋白水解酶的激活有关。如果情况确实如此,组织蛋白酶抑制剂可为软骨肉瘤提供急需的辅助治疗。